Healthcare IT Today September 23, 2024
Human Longevity, Inc. (HLI), with over 10 years as a longevity-focused technology company, today announced the completion of an oversubscribed $39.8M Series B round led by TVM Capital Healthcare with participation from new and existing investors, including Panacea Venture and Emerging Technology Partners. The funding will be used to invest in HLI’s artificial intelligence health risk and recommendation platform, new longevity-focused technologies and services, and new expansion sites globally.
Founded in 2013, with a group of pioneers in the precision medicine field, HLI has made significant research and development progress in the longevity field. In 2020, the company published groundbreaking research in the Proceedings of the National Academy of Sciences, demonstrating the integration of whole-genome sequencing, comprehensive metabolomics, and advanced...